Therma Bright Stock Price, News & Analysis

Therma Bright Inc. (OTCQB: TBRIF) is a developer and investment partner focused on advanced diagnostic and medical device technologies that address key healthcare challenges. The company is listed on the TSX Venture Exchange under the symbol THRM and on the Frankfurt Stock Exchange under the symbol JNX0/JNX. Its activities combine the development of its own medical devices with strategic investments in complementary healthcare technologies.

Therma Bright describes its core focus as developing and partnering on diagnostic and medical device technologies. This includes working with national and specialized distributors, engaging in product manufacturing strategy, and supporting investee companies that are developing novel therapies. The company’s approach involves both direct commercialization of its flagship device and indirect value creation through investment and advisory roles with emerging healthcare ventures.

Venowave VW5 medical device

A central product for Therma Bright is the Venowave VW5, described as a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders in the lower limbs. When positioned or strapped below the knee, the device generates a gentle, wave-like or wave-form motion that compresses the calf, promoting improved venous blood circulation and lymphatic function and upward displacement of venous and lymphatic fluid.

The Venowave VW5 is identified as an FDA-designated Durable Medical Equipment (DME) device. It is built for durability and supports repeated use across multiple patients. The device is powered by a single rechargeable 1.5V NiMH AA battery, allowing users to receive treatment while staying active. Therma Bright notes that Venowave qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, and that it is the only Medicare-approved reimbursable mobile mechanical compression system available in the U.S. under its HCPCS code E0683.

Clinical information disclosed by the company states that Venowave has been shown to enhance venous blood flow by 64% after two minutes of use and 88% after 50 minutes. Therma Bright positions Venowave as a treatment that can accelerate post-operative recovery while managing pain and swelling, and as a solution that can reduce post-surgical complications and costly readmissions in specific patient groups, such as those undergoing specialized knee surgeries.

Commercial strategy and distribution

Therma Bright’s commercial activities for Venowave include working with distributors in the Durable Medical Equipment (DME) sector and specialized medical product distributors. The company has highlighted an initial purchase order for 200 Venowave VW5 units from a key DME distributor, which plans to introduce the device to its established customer base. Therma Bright has also announced a partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas, following an initial 200-unit sale targeting patients who had undergone specialized knee surgeries.

According to statements from Therma Bright and its partners, the Venowave VW5 is being positioned within focused, high-value segments of the U.S. healthcare market, including patients recovering from specialized knee procedures and individuals suffering from vascular issues such as deep vein thrombosis. The company also notes that it continues to work with national distributors to expand Venowave’s market presence.

Manufacturing and supply chain considerations

Therma Bright has disclosed that Venowave is manufactured in China for the U.S. market and that evolving U.S. tariff policies on foreign-manufactured goods have prompted a review of its manufacturing strategy. The company is evaluating options including onshoring or establishing manufacturing capabilities within North America (Canada, USA, or Mexico), as well as hybrid approaches that combine manufacturing of Venowave or component parts in China with onshoring in North America.

In its assessment, Therma Bright indicates that it is considering factors such as supply chain resilience, lead times, quality control, intellectual property protection, logistics and transportation, and market access and geopolitical stability. The company emphasizes that no final decision has been made and that its review is intended to ensure the long-term competitiveness and stability of its supply chain for Venowave.

Investment partner role and InStatin involvement

Beyond its own devices, Therma Bright acts as a developer and investment partner in advanced healthcare technologies. A notable example is its role as an investment partner in InStatin, a preclinical-stage biotechnology company dedicated to repurposing statins for inhaled delivery to treat inflammatory respiratory diseases, beginning with Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Therma Bright has reported on InStatin’s progress, including refinement of clinical strategy, advancement of its lead molecule INS-102, and expansion of its leadership and advisory teams. InStatin is developing inhaled statin therapies for respiratory diseases and has designated COPD as its lead clinical indication, while continuing to include asthma in its development plans. Preclinical studies described by InStatin have identified INS-102 as a lead statin candidate with improved pharmacokinetics and longer lung residence time compared to earlier candidates, and a proprietary dry powder formulation has undergone pharmacokinetic testing in animals.

Therma Bright has also highlighted InStatin’s intellectual property activities, including licensed patents under international examination and a provisional patent on novel inhaled statin formulations. The company notes that InStatin is pursuing funding to advance to proof-of-concept clinical studies and is presenting at healthcare investment and innovation conferences.

Corporate actions and capital structure updates

Therma Bright has disclosed several corporate actions related to its capital structure. The company announced a share consolidation on the basis of eight pre-consolidation common shares for one post-consolidation common share. It indicated that this consolidation was approved by the Board of Directors under the company’s Articles of Incorporation and that the consolidation was intended to provide increased flexibility in structuring and completing financings and potential business transactions.

The company has also reported proposed and completed amendments to the exercise price of outstanding common share purchase warrants, subject to TSX Venture Exchange approval and in compliance with Multilateral Instrument 61-101 regarding related party transactions. In addition, Therma Bright has negotiated debt settlements with arm’s length creditors, settling certain amounts of debt through the issuance of common shares at specified deemed prices, again subject to TSXV acceptance.

Governance and board composition

Therma Bright has reported changes to its Board of Directors, including the appointment of a U.S. healthcare industry veteran to the Board. This individual, previously a member of Therma Bright’s advisory board, brings commercial leadership experience in healthcare and business services and is expected, according to the company, to support market penetration and sales growth of Venowave through internal sales team development and partnerships with medical device resellers. Therma Bright has also announced the resignation of a board member, thanking the individual for their service.

Industry context and classification

Based on the provided classification, Therma Bright is associated with the Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers industry within the Wholesale Trade sector. Its disclosed activities—developing and commercializing a durable medical equipment device, working with DME distributors and specialized medical product distributors, and acting as an investment partner in medical and diagnostic technologies—align with this characterization.

Status and trading

Available information indicates that Therma Bright Inc. trades on the TSX Venture Exchange under the symbol THRM, on the OTCQB under the symbol TBRIF, and on the Frankfurt Stock Exchange under the symbol JNX or JNX0. The company has not reported delisting, bankruptcy, or acquisition in the provided materials. Its disclosures focus on product commercialization, investment activities, manufacturing strategy, capital structure adjustments, and governance changes.

Key points for investors and observers

• Therma Bright develops and partners on diagnostic and medical device technologies, with Venowave VW5 as its flagship vascular compression therapy device.
• The company positions Venowave as an FDA-designated DME device that is Medicare- and Medicaid-reimbursable under a specific HCPCS code and multiple medical indications.
• Therma Bright works with DME and specialized distributors, including Gen-X Med, to introduce Venowave to targeted patient populations, such as those undergoing specialized knee surgeries.
• The company is actively reviewing manufacturing options for Venowave in response to U.S. tariff changes, including potential onshoring or hybrid production models.
• As an investment partner, Therma Bright supports InStatin, a preclinical-stage biotech focused on inhaled statin therapies for COPD and asthma, and reports on its scientific, clinical, and IP progress.
• Corporate actions disclosed include share consolidation, warrant repricing (subject to TSXV approval), and debt settlements through share issuance.